Home › Oropharyngeal Cancer › Iowa › Cedar Rapids
Oropharyngeal Cancer clinical trials in Cedar Rapids, IA
3 studies for Oropharyngeal Cancer are looking for participants at sites in and around Cedar Rapids (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi away
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Oropharyngeal Cancer trials in other cities
- Atlanta, GA8 studies
- Edison, NJ8 studies
- Chicago, IL7 studies
- New York City, NY6 studies
- Queens, NY5 studies
- St. Louis, MO5 studies
- Tampa, FL5 studies
- Kansas City, MO5 studies
- Pittsburgh, PA5 studies
- Milwaukee, WI5 studies
- Omaha, NE5 studies
- Philadelphia, PA5 studies
Other studies in Cedar Rapids
- Non-Small Cell Lung Cancer20 studies
- Breast Cancer17 studies
- Cancer (all types)16 studies
- Acute Myeloid Leukemia16 studies
- Multiple Myeloma15 studies
- Lung Cancer14 studies
- Colorectal Cancer13 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Prostate Cancer12 studies
- Stroke10 studies
- Melanoma10 studies
- Endometrial Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.